

Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance

Inder S,^{1,2} Bates M,¹ Ni Labhrai N,¹ McDermott N,¹ Schneider J,³ Erdmann G,³ Jamerson T,⁴ Flores A,⁴ Prina-Mello A,⁵ Thirion P,⁶ Manecksha P. R,^{2,7} Cormican D,⁸ Finn S,⁸ Lynch T,² Marignol L^{1*}

¹Translational Radiobiology and Molecular oncology, Applied Radiation Therapy Trinity, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Ireland

²Department of Urology, St James's Hospital, Dublin, Ireland

³NMI TT Pharmservices, Berlin, Germany

⁴Department of International Health, Mount Sinai School of Medicine, New York, USA


⁵Laboratory for Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute (TTMI), AMBER centre at CRANN Institute, Trinity College Dublin, Ireland; Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Ireland.

⁶St Luke's Radiation Oncology Network, St James's Hospital, Dublin, Ireland


⁷Department of Surgery, Trinity College Dublin, Ireland

⁸Department of Histopathology, St James's Hospital, Dublin, Ireland


Supplementary Figure 1A: Full PARP-1 immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer. Three independent biological replicates, noted as 1, 2, and 3 are presented. PARP-1 antibody, Santacruz, sc-8007, 1:100, 10s Exposure.




Supplementary Figure 2A Full Androgen Receptor (AR) immunoblot of the cytoplasmic (C) and nuclear (N) protein fraction of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer.




Supplementary Figure 2B Full Lamin immunoblot of the cytoplasmic (C) and nuclear (N) protein fraction of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer.




Supplementary Figure 2C Full GAPDH immunoblot of the cytoplasmic (C) and nuclear (N) protein fraction of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer.



Supplementary Figure 3A: Full p53 immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer. Three independent biological replicates are presented.



Supplementary Figure 3B: Full GAPDH immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer. Three independent biological replicates are presented.



← GAPDH 39kDa

Supplementary Figure 4: Full Notch-3 and Actin immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer.




Figure 5A Full Notch-3 immunoblot of cell lysates of untreated (Controls) and 5Gy- irradiated 22Rv1, DU145 and PC3 prostate cancer cells.




Figure 5B Full HES-1 immunoblot of cell lysates of untreated (Controls) and 5Gy- irradiated 22Rv1, DU145 and PC3 prostate cancer cells.







Figure 5C Full Tubulin immunoblot of cell lysates of untreated (Controls) and 5Gy- irradiated 22Rv1, DU145 and PC3 prostate cancer cells.



Supplementary Figure 6A: Full YB-1 immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer. Three independent biological replicates are presented. HeLa cell lysates were used as a control. MM, Molecular Marker.



Supplementary Figure 6B: Full Vinculin immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer. Three independent biological replicates are presented. HeLa cell lysates were used as a control.



Supplementary Figure 6C: Full Lamin immunoblot of wild type (WT), age-matched controls (AMC) and radioresistant (RR) 22Rv1 prostate cancer. Three independent biological replicates are presented. HeLa cell lysates were used as a control..

